Company: ISRG
Filing Date: 2025-04-23
Form Type: 10-Q
Source: 0001035267-25-000109
Chunk: 111

Company: INTUITIVE SURGICAL INC
Filing Date: 2025-04-23
Form: 10-Q
Item: Item 1A
Chunk 111
---
ITEM 1A.    RISK FACTORS

You should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial position, or future results of operations.

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of equity securities during the period covered by this report.

(c) Issuer Purchases of Equity Securities

The table below summarizes our stock repurchase activity for the quarter ended March 31, 2025:

Fiscal PeriodTotal Numberof SharesRepurchasedAverage Price PaidPer ShareTotal Number of Shares Purchased As Part of a Publicly Announced ProgramApproximate Dollar Amount of Shares That  May Yet be Purchased Under the Program (1)January 1 to January 31, 2025— $— — $1.1  billionFebruary 1 to February 28, 2025— $— — $1.1  billionMarch 1 to March 31, 2025— $— — $1.1  billionTotal during quarter ended March 31, 2025— $— — 

(1) Represents the cumulative amount remaining for stock repurchases under the Board-authorized Repurchase Program established in March 2009. In July 2022, the Board increased the authorized amount available under our Repurchase Program by $3.5 billion. Authorizations under the Repurchase Program do not expire.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.    MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.    OTHER INFORMATION

Rule 10b5-1 Plans

On January 29, 2025, Amy L. Ladd, M.D., a member of the Company’s Board of Directors, adopted a